HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.

Abstract
Macitentan is a dual endothelin receptor antagonist under phase 3 investigation in pulmonary arterial hypertension. We investigated the effect of cyclosporine (Cs) and rifampin on the pharmacokinetics of macitentan and its metabolites ACT-132577 and ACT-373898 in healthy male subjects. In addition, in vitro studies were performed to investigate interactions between macitentan and its active metabolite ACT-132577 with human organic anion-transporting polypeptides (OATPs). The clinical study (AC-055-111) was conducted as a two-part, one-sequence, crossover study. Ten subjects in each part received multiple-dose macitentan followed by multiple-dose co-administration of Cs (part A) or rifampin (part B). In the presence of Cs, steady-state area under the plasma concentration-time profiles during a dose interval (AUC(τ)) for macitentan and ACT-373898 increased 10% and 7%, respectively, and decreased 3% for ACT-132577. Steady-state AUC(τ) of macitentan and ACT-373898 in the presence of rifampin decreased 79% and 64%, respectively. For ACT-132577, no relevant difference in AUC(τ) between the two treatments was observed. Macitentan co-administered with Cs or rifampin was well tolerated. The complementary in vitro studies demonstrated no marked differences in uptake rates of macitentan and ACT-132577 between the wild-type and OATP over-expressing cells over the concentration range tested. Concomitant treatment with Cs did not have any clinically relevant effect on the exposure to macitentan or its metabolites, at steady-state. Concomitant treatment with rifampin reduced significantly the exposure to macitentan and its metabolite ACT-373898 at steady-state but did not affect the exposure to the active metabolite ACT-132577 to a clinically relevant extent.
AuthorsShirin Bruderer, Päivi Aänismaa, Marie-Claude Homery, Stephanie Häusler, Kyle Landskroner, Patricia N Sidharta, Alexander Treiber, Jasper Dingemanse
JournalThe AAPS journal (AAPS J) Vol. 14 Issue 1 Pg. 68-78 (Mar 2012) ISSN: 1550-7416 [Electronic] United States
PMID22189899 (Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • ACT-373898
  • Endothelin A Receptor Antagonists
  • Endothelin B Receptor Antagonists
  • Organic Anion Transporters
  • Pyrimidines
  • Sulfonamides
  • Cyclosporine
  • aprocitentan
  • Rifampin
  • macitentan
Topics
  • Adult
  • Animals
  • Area Under Curve
  • CHO Cells
  • Cricetinae
  • Cricetulus
  • Cross-Over Studies
  • Cyclosporine (administration & dosage, pharmacology)
  • Drug Interactions
  • Endothelin A Receptor Antagonists
  • Endothelin B Receptor Antagonists
  • Humans
  • Male
  • Organic Anion Transporters (metabolism)
  • Pyrimidines (administration & dosage, pharmacokinetics)
  • Rifampin (administration & dosage, pharmacology)
  • Sulfonamides (administration & dosage, pharmacokinetics)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: